Nucleic Acid Extraction Patents: Who Leads, Where the Gaps Are 2026
- Filing peaked in 2021 at 243 records and has fallen 41% by 2024 (243 → 143), the last year the dataset treats as complete.
- The field is not a two-horse race the leader holds 183 records but the top 5 combined account for only 17.7% of all 2,912 records in scope — a long tail follows.
- Claim activity concentrates in assay chemistry, not hardware C12Q covers 60.7% of records versus 21.3% for lab-apparatus class B01L, a gap worth noting before filing a device claim.
Filing growth compares 2021 (243 records) with 2024 (143) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,912 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape covers 2,912 published patent families filed against automated nucleic acid extraction — magnetic bead workflows, lysis chemistry, inhibitor removal, elution volume control, cross-contamination prevention and the plastic consumables that carry a sample through the process. The scope spans both the biochemistry side (lysis buffers, wash steps, elution) and the instrument side (cassettes, cartridges, robotic handling), which is why a single record often carries several IPC classes at once.
Filings run from 2015 through the 2026-07-31 data cut-off, with the most recent one to two years understated because publication typically lags filing by around 18 months. Reading the trend, the leaderboard and the technology mix together gives a more reliable picture than any single chart.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend, technology mix and receiving offices
Three views of the same 2,912-record dataset: when filings happened, what technical classes they sit in, and where applicants sought protection.
Filing trend
Filings rose from 160 in 2017 to a peak of 243 in 2021, then declined to 143 by 2024 — a 41% drop over that three-year span. Treat 2025 and 2026 figures as incomplete rather than as evidence the field is winding down.
Technology composition
C12Q (enzyme/DNA measuring and testing) appears in 60.7% of the 2,912 records, well ahead of C12N genetic-engineering classes at 29.3% and general material analysis under G01N at 27.8%. Lab apparatus (B01L) and bioreactor/enzyme apparatus (C12M) classes sit lower, at 21.3% and 16.9% respectively, and bioinformatics (G16B) and sugars/nucleic-acid chemistry (C07H) trail at 7.6% and 4.7%. Because records can carry multiple classes, these shares add up to more than 100% and should each be read against the 2,912-record total, not against one another.
Shares are the percentage of the 2,912 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Nucleic Acid Extraction Automation with Eureka
This page is one run against one query. Ask Eureka your own question about nucleic acid extraction automation and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in this dataset
Automated nucleic acid extraction method and device (US20220017890A1)
The device arranges a sample area, column area, cassette area and collection tube in a linear layout, with a cassette whose parallel and vertical walls form dedicated lysis, wash and elution buffer wells, each vertical wall carrying a load-bearing abutment engaged by a driving unit and moving frame with syringe.Filed by Catchgene Co., Ltd., published 2022-01-20.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20060177855A1 | Nanoparticles for manipulation of biopolymers and methods of thereof | 727 |
| 2 | US7101663B2 | PCR method | 393 |
| 3 | US20090130745A1 | Integrated Apparatus for Performing Nucleic Acid Extraction and Diagnostic Testing on Multiple Biological Sam… | 381 |
| 4 | US20050221281A1 | Self-contained microfluidic biochip and apparatus | 339 |
| 5 | WO2012012779A2 | System and method including analytical units | 326 |
| 6 | US8133671B2 | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological sam… | 322 |
| 7 | US20030049833A1 | Sample vessels | 267 |
| 8 | US20090130719A1 | Microfluidic Cartridge | 248 |
| 9 | US20040063217A1 | Miniaturized fluid delivery and analysis system | 247 |
| 10 | US20090221059A1 | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological sam… | 232 |
Citation counts inside this corpus favour older filings and should be read as a signal of influence within the searched set, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four read-outs from the dataset that matter more for strategy than the raw counts alone.
Peak has passed, not disappeared
Filings fell 41% from the 2021 peak of 243 to 143 in 2024, the most recent year the dataset treats as complete. That is consistent with a maturing claim space rather than an abandoned one — 2025 and 2026 counts are still filling in under the usual 18-month publication lag.
A leader, then a long tail
The top assignee holds 183 records and fifth place holds 61, but the top 5 combined still account for only 17.7% of all 2,912 records in scope, rising to 26.4% for the top 10. Most of the field sits outside the ranked leaders entirely.
Chemistry claims outweigh hardware claims
C12Q measuring/testing claims cover 60.7% of the 2,912 records against 21.3% for B01L lab apparatus, suggesting the denser prior art sits in assay chemistry and workflow logic rather than physical cassette or instrument design.
US-first filing strategy dominates
The United States leads receiving offices at 854 filings, ahead of the EPO at 573 and WIPO/PCT at 448, with Australia, China and Canada each in the low hundreds — a pattern typical of a field with strong US clinical-diagnostics commercialisation.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to nucleic acid extraction automation, with the prior art for and against each one.
Who holds the ranked positions
The assignee ranking covers 100 companies counted in records — the full ranking the dataset returns, not a curated top list. Positions run from a leader at 183 records down through a long tail of single- and few-filing entrants.
One clear leader, moderate lead
The top-ranked assignee holds 183 records, well ahead of fifth place at 61 and tenth place at 47 — a real lead, but not a dominant one given the top 5 combined still total only 17.7% of all 2,912 records.
Even leaders have gone quiet recently
Several of the most-ranked assignees show sharply reduced or zero activity in the latest year, including drops as steep as -85% and -100% year-on-year. This tracks the overall post-2021 decline rather than signalling exits by any single filer.
Filing is mostly solo, with a few tight pairs
Only 10 co-assignee pairs appear in the dataset, and the strongest pairing recurs across multiple joint filings — evidence of a small number of durable research partnerships rather than a broad collaboration network.
| Assignee | Recent year | YoY |
|---|---|---|
| Foundation Medicine Inc. | 2 | -85% |
| HandyLab Inc. | 0 | — |
| Qiagen GmbH | 0 | -100% |
| Quest Diagnostics Investments Inc. | 0 | — |
| California Institute of Technology | 0 | — |
| Beckman Coulter Inc. | 0 | — |
| Purigen Biosystems Inc. | 0 | -100% |
| Visby Medical Inc. | 0 | -100% |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy or identifying open filing space.
Check freedom-to-operate against the most-cited records
The highest-citation documents in this set, several dating to the mid-2000s and 2010s, still anchor claim language across newer filings in cassette design and integrated extraction-to-detection systems.
Explore citation network in EurekaMap the white space in bioinformatics-linked extraction QC
G16B bioinformatics classes appear in only 7.6% of records despite growing interest in automated quality control for extraction yield, suggesting room for claims that pair extraction hardware with data-driven QC logic.
Run a white space search in EurekaTrack momentum shifts among the ranked leaders
Several top-ranked assignees show steep year-on-year declines in the latest partial year; watching whether this continues once 2025-2026 data fills in will clarify whether the field is consolidating or simply pausing.
Set up assignee monitoring in EurekaCommon questions on this landscape
The ranking covers 100 assignees counted in records, with the leader holding 183 records and fifth place holding 61. The top 5 combined account for 17.7% of all 2,912 records in scope, and the top 10 combined reach 26.4%, which means most of the field's activity sits outside the ranked leaders in a long tail of smaller filers. This spread matters for freedom-to-operate work: no single company controls enough of the space to be the sole gatekeeper.
Filings peaked at 243 in 2021 and fell to 143 by 2024, a 41% decline over that three-year span, which is the most recent period the dataset treats as complete. Counts for 2025 and 2026 are still low but should not be read as a continued slowdown, since publication typically lags actual filing by around 18 months. The honest read is that the field passed its filing peak in 2021 and has since settled to a lower but still active rate.
C12Q, covering enzyme and DNA measuring and testing methods, appears in 60.7% of the 2,912 records and is the single densest class. C12N genetic-engineering claims follow at 29.3% and general material analysis under G01N at 27.8%, while physical lab-apparatus claims under B01L sit lower at 21.3%. This pattern suggests the more contested claim space is in assay chemistry and workflow logic rather than in cassette or instrument hardware design.
Bioinformatics integration under G16B appears in only 7.6% of records and sugars/nucleic-acid chemistry under C07H in just 4.7%, both notably thinner than the core C12Q and C12N classes. Combining automated extraction hardware with data-driven yield or contamination QC, or filing more specifically on elution-volume optimisation tied to downstream sequencing requirements, looks comparatively under-claimed relative to the density elsewhere in the dataset. These are starting points for a novelty search, not guarantees of open ground.
The United States leads as a receiving office with 854 filings, ahead of the European Patent Office at 573 and the WIPO/PCT route at 448. Australia, China and Canada follow at lower but still meaningful counts of 210, 181 and 142 respectively. This distribution reflects where applicants sought protection, not necessarily where the underlying research or manufacturing takes place, so it should be paired with assignee nationality data for a fuller geographic picture.
Research Nucleic Acid Extraction Automation in depth with Eureka
Go past this page: query the whole nucleic acid extraction automation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.